Dr Lal PathLabs may raise FY27 margin guidance after first-half results
The diagnostics chain reported 19% year-on-year Q1 revenue growth and a 31% EBITDA margin, above its FY27 guidance of 27%-28%. It is also assessing acquisitions to deepen its presence in South India and Gujarat.
Dr Lal PathLabs may raise FY27 margin guidance after first-half results if trends persist. The diagnostics chain will prioritise growth investments and evaluate acquisitions to strengthen its presence in South India and Gujarat.
Why this matters
No related recent Dr Lal PathLabs signals are listed. The potential FY27 guidance increase follows a Q1 margin beat and a review of acquisitions in South India and Gujarat.
Retail-company signals are accelerating, up 568650% QoQ.